The FDA’s decision to allow the compounding of GLP-1 weight loss drugs could undermine its public health obligations, writes ...

Pharmacies that make customized medications are asking the federal Food and Drug Administration to protect their right to ...

The Food and Drug Administration allows for licensed compounding pharmacies to make copies of certain drugs in short supply, and that has included semaglutide and tirzepatide, the main ingredients in ...

Modern medical innovations continue to transform treatment approaches for chronic conditions, and Ozempic stands at the ...

Research suggests that there may be safer ways of supressing your appetite without resorting to weight-loss drugs.

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out drugs are emerging.

In an essay for 'Women's Health,' Dr. Nora Volkow discusses the future of semaglutide weight-loss meds, and their potential ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

Novo Nordisk, which manufactures weight-loss drug Wegovy and diabetes medication Ozempic, has asked the US authorities to ...

While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its ...

Semaglutide and a similar compound, tirzepatide, had been on the FDA’s shortages list since 2022, and the popularity of the ...

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...